Sirigen Raises $6.1M for Technology Commercialization | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK amplification firm Sirigen today announced it has raised about £3.8 million ($6.1 million) in two completed rounds of financing, which it will use to support commercialization of its High Sensitivity Fluorescence technology.

Leading the rounds was a syndicate of new investors including IQ Capital, the National Endowment for Science, Technology, and the Arts, and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.